Development and validation of a risk score for serious infection in patients with rheumatoid arthritis.
about
Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsDose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritisEvaluation of the RABBIT Risk Score for serious infectionsRheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis.Vaccinations for rheumatoid arthritis.The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effectsPrevalence and microbiological characteristics of clinically infected foot-ulcers in patients with rheumatoid arthritis: a retrospective exploratory studyNew methods for determining comparative effectiveness in rheumatoid arthritisTrends in serious infections in rheumatoid arthritis.Risk factors for infection following total joint arthroplasty in rheumatoid arthritis.The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial.Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis.The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.The influence of ageing on the development and management of rheumatoid arthritis.Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease.Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study.The association between serious infection and disease outcome in patients with rheumatoid arthritis.The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients.Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study.Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis.Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.Diabetes and the occurrence of infection in primary care: a matched cohort study.
P2860
Q28073436-6C6C68A3-CCFA-4F91-A73A-A297783080DEQ33841390-F0B571C7-3BC2-495D-AB14-F2C63490CED2Q34092564-621661F5-FC8D-4595-A52C-FD8C4CA7E105Q34388430-1D7FDCE7-C0D3-4C65-828B-C5FA436AD6D2Q34424563-198894EE-8567-45BA-AAEB-88A97CE440CCQ34597321-4F6B1227-D043-4B0B-A426-5537E65B703CQ35957200-6D0D301B-AFB7-43AD-9BB6-C090ADD51D4DQ37274242-352B0F9F-F572-4FDA-9337-1C3411666E13Q37453987-9CAF60FF-1B55-4BF4-A0FB-FD324F5A62B2Q37486363-B6B46C0A-9B87-4962-BBFA-44BAE93A402DQ37604999-F4F23ED1-57AB-4E0F-BF15-FCEBA2F87A18Q37643408-E89BD6D6-012C-42E0-A03A-7C62DC94F74FQ38063474-1535F4AB-96AA-49D3-A6EF-92880E4E4ED8Q38115131-66EFDF9B-0E34-4DF2-AD49-0244518B1E4EQ38757421-972A9FEF-0F4F-4D0C-9CA8-C427B1595FEAQ39570333-AF193E1C-67BC-4855-8283-5404F111C71BQ40305897-A697A26C-8AA9-468C-8CFD-DCDA51F3B2E1Q40868036-2C533A57-3459-4C79-9C47-2CA4270B2B9DQ41471703-54137CB2-FEA3-4974-BA72-8F8FEA339D66Q45098990-5FDB00A8-133E-43BA-B708-B43E9FB99C8FQ45929880-59AE32D2-7C15-4A1C-A885-0D8993FF3975Q46299592-60DDFC3E-C606-4F9B-813E-BFD6F3EF0749Q47120472-28555796-E6AE-4589-91C4-63708769FCDFQ48104054-542301D6-462C-4043-A4D5-0A91508577A0
P2860
Development and validation of a risk score for serious infection in patients with rheumatoid arthritis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Development and validation of ...... nts with rheumatoid arthritis.
@ast
Development and validation of ...... nts with rheumatoid arthritis.
@en
type
label
Development and validation of ...... nts with rheumatoid arthritis.
@ast
Development and validation of ...... nts with rheumatoid arthritis.
@en
prefLabel
Development and validation of ...... nts with rheumatoid arthritis.
@ast
Development and validation of ...... nts with rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Development and validation of ...... nts with rheumatoid arthritis.
@en
P2093
Cynthia S Crowson
Deana D Hoganson
Eric L Matteson
Patrick D Fitz-Gibbon
P2860
P304
P356
10.1002/ART.34530
P577
2012-09-01T00:00:00Z